Maitake and Type 2 Diabetes: Evidence and Mechanisms

Maitake & Blood Sugar / Diabetes

63% max fasting glucose decline

In the only published pilot study of maitake SX-fraction in type 2 diabetes patients, fasting blood glucose fell between 30% and 63% in 7 patients over two to four weeks — while they were already taking oral diabetes medication.

Konno, Int J Gen Med, 2013

9 patients

total published human subjects across both T2DM maitake studies

4 pathways

distinct glucose-lowering mechanisms identified in preclinical research

2019–2021

gut microbiota studies reveal a mechanism most maitake research ignored

Konno, Int J Gen Med, 2013

View as image ↗

A 2020 review set out to catalog every clinical trial on medicinal mushrooms for type 2 diabetes treatment.^[1] The authors found something awkward: rigorous human trials were almost entirely absent — not just for maitake, but for every medicinal mushroom species studied. That honest starting point matters for understanding the maitake mushroom type 2 diabetes research landscape. The preclinical case is genuinely compelling, built on three decades of consistent animal evidence and four distinct mechanisms. But the human data is small, and anyone claiming otherwise hasn't read the papers.

This article covers what the evidence actually shows: where the human data ends, how the animal research maps out, and which mechanistic pathways the research has identified — including one that almost no competitor site has covered. For a broader introduction to maitake, see What Is Maitake Mushroom? The Dancing Mushroom Explained.

Where the Evidence Stands: 30 Years of Research, Almost No Human Trials

Lindequist and Haertel's 2020 review of clinical trials on medicinal mushrooms for type 2 diabetes reached a direct conclusion: the evidence is promising in animal models, but rigorous human randomized controlled trials are largely absent across all medicinal mushroom species, maitake included.^[1]

That doesn't mean the research is weak. It means the human trials haven't been run yet.

An earlier Natural Standard systematic review from 2009 surveyed the evidence through that point and landed in the same place: maitake showed promising preclinical results for diabetes, immune function, and cancer support, but the absence of rigorous human trials made definitive clinical recommendations premature.^[4]

The most comprehensive summary of the specific maitake extract most studied for blood sugar — the SX-fraction — came in a 2020 review by Konno, published in World Journal of Diabetes.^[2] It covered the full arc: animal studies, in vitro mechanism work, and the two small pieces of human data that exist. Its conclusion was that SX-fraction appears safe and effective in preclinical models, with limited human pilot data pointing in the same direction — but that larger randomized trials are needed before clinical conclusions can be drawn.

The honest frame for everything that follows: the preclinical evidence is real, consistent, and mechanistically rich. The human evidence is limited but intriguing. Those are different things, and conflating them is how competitors have gotten this topic wrong.

The Entire Human Record: 9 Patients, Two Publications

The strongest evidence summary for maitake and type 2 diabetes is a short one. Here is the complete published human record:

Nine patients total. No control groups in either publication. No blinding. These are the data points that almost every supplement brand presents as "clinical evidence that maitake treats diabetes."

That's not what they are. They are early-phase signals that something worth testing is happening. The mechanism has been characterized at the cellular level. The direction of the effect in limited human data is consistent with the animal evidence. The next logical step — a properly powered randomized controlled trial — hasn't been funded.

What the 7-Patient Pilot Actually Found

The 2013 study by Konno, published in the International Journal of General Medicine, did two things at once.^[3] In the laboratory, it showed that SX-fraction activates the insulin receptor — the protein on muscle cell surfaces that insulin binds to — and its immediate downstream partner, IRS-1 (insulin receptor substrate-1). Activate those two proteins and glucose uptake follows. The mechanism explains why blood glucose falls.

In the clinical portion, 7 patients with type 2 diabetes who were already taking oral diabetes medications received SX-fraction supplementation. Over two to four weeks, their fasting blood glucose fell between 30% and 63%. No adverse effects were reported.

The obvious limitation: 7 patients with no control group. The glucose reductions could reflect natural variation in blood glucose, better compliance with existing medications, or something else entirely. What it provides is a directionally consistent signal, a characterized mechanism, and a clean safety record — which is exactly what early-phase human work is supposed to establish.

The 2-Patient Letter

The earlier piece of human data — a 2001 letter to the editor by Konno and colleagues in the Journal of Orthomolecular Medicine — reported that two type 2 diabetes patients experienced approximately 30% reductions in blood glucose after consuming whole maitake powder. This is the publication routinely cited by supplement websites as "clinical evidence" for maitake lowering blood sugar. It is a 2-patient letter, not a clinical trial. Both pieces of human data point in the same direction, but neither constitutes strong clinical evidence on its own.

Four Mechanisms Explaining Why Animal Studies Keep Showing Results

The reason the animal literature is convincing isn't any single effect size — it's consistency. The same outcome (lower blood glucose, improved insulin sensitivity) appears across independent studies, multiple animal models, and four distinct mechanisms. That's different from one research group finding one result.

GLUT4 Upregulation: Opening Glucose Channels in Muscle and Liver

One of the clearest mechanistic findings comes from a 2015 study by Xiao and colleagues, published in Food and Function.^[5] Two maitake polysaccharide fractions — F2 and F3 — were tested in streptozotocin-induced diabetic rats. Both reduced fasting blood glucose, improved the animals' response to a glucose challenge (the oral glucose tolerance test), and decreased a standard marker of insulin resistance.

The specific finding that stands out: F2 and F3 polysaccharides directly increased the expression of GLUT4 in liver tissue. GLUT4 is the protein that acts as a glucose door — it embeds in cell membranes in response to insulin signaling and allows glucose to enter the cell. In type 2 diabetes, cells stop responding properly to insulin, and fewer GLUT4 doors appear at the surface. Maitake polysaccharides appear to directly upregulate GLUT4 expression, partially restoring that transport capacity regardless of whether the insulin signal is working properly.

This is mechanistically distinct from how most diabetes drugs work. Most oral diabetes drugs either stimulate insulin secretion from the pancreas or improve the liver's response to insulin at the signaling level. Increasing GLUT4 expression in peripheral tissue represents a different intervention point in the glucose regulation chain.

A comprehensive metabolic picture from Hong and colleagues in 2007 adds context.^[6] Testing an alpha-glucan fraction from maitake in KK-Ay diabetic mice — a genetic model with high insulin resistance — the study found simultaneous improvements in fasting plasma glucose, circulating insulin levels, triglycerides, cholesterol, and liver malondialdehyde (a marker of oxidative stress in liver tissue). The breadth of metabolic improvement from a single fraction in one experiment suggests maitake's effects extend well beyond glucose in isolation. For readers interested in the hepatic aspects of this finding, see Maitake and Liver Health: Hepatoprotective Effects.

The Gut Microbiota Connection: The Mechanism Most Maitake Research Has Missed

Between 2019 and 2021, three independent research groups published findings connecting maitake's blood glucose effects directly to changes in gut bacteria. This is the cutting edge of the maitake diabetes research, and it is almost entirely absent from competitor content.

Chen and colleagues, writing in Food and Chemical Toxicology in 2019, found that a novel maitake polysaccharide improved type 2 diabetes in mice through two routes simultaneously.^[7] First, through the insulin signaling pathway — specifically the chain of molecular events connecting the insulin receptor to GLUT4 expression (IRS1/PI3K/GLUT4/JNK). Second, by rebalancing gut bacteria: the polysaccharide increased beneficial bacteria (Bifidobacterium and Lactobacillus) and decreased harmful bacteria (Clostridium). The gut bacteria changes correlated with the blood glucose improvements, suggesting both pathways reinforce each other.

Guo and colleagues published a closely parallel finding in the International Journal of Biological Macromolecules in 2020.^[8] Maitake polysaccharides in diabetic mice reduced fasting blood glucose and triglycerides simultaneously, and both effects correlated with changes in the gut microbiota community. The joint improvement — blood sugar and blood lipids both moving in the right direction — suggests the gut-microbiota pathway drives a broader metabolic effect, not just glucose in isolation.

Pan and colleagues, also in 2020, confirmed the gut-glucose connection through a complementary angle.^[9] A maitake extract combining polysaccharides and organic acids normalized both glycolipid metabolism and gut microbiota composition in rats. The extract reshaped the bacterial community while improving blood glucose and lipid markers — establishing gut rebalancing as a core mechanism, not a coincidental finding.

Why does this matter? An unhealthy gut bacteria community (called dysbiosis) can drive systemic inflammation via a bacterial component called LPS (lipopolysaccharide). That inflammation impairs insulin signaling throughout the body. A polysaccharide that rebalances gut bacteria may interrupt that inflammatory cascade at its source. This is mechanistically distinct from GLUT4 upregulation or insulin receptor sensitization, and it represents a completely new lens for understanding why maitake's effects replicate across so many animal models.

The Ceramide Pathway: How Maitake Targets Obesity-Linked Insulin Resistance

Type 2 diabetes and obesity are tightly linked. Excess fat — particularly in and around the liver and organs — directly impairs insulin signaling through multiple routes. One of those routes involves lipid molecules called ceramides, which accumulate in fat tissue and send signals that shut down insulin action in muscle and liver cells.

A 2021 study by Jiang and colleagues, published in Food and Function, tested maitake polysaccharides in mice fed a high-fat diet.^[10] The polysaccharides reduced obesity markers — less body fat accumulation, lower triglycerides, lower cholesterol — and the mechanism traced to ceramide pathway modulation. By targeting the ceramide signaling route, maitake may address one of the main reasons insulin resistance develops in the first place: the fat-accumulation-driven impairment of insulin action.

This is relevant specifically for type 2 diabetes because most people with the condition have meaningful adiposity (excess fat). Targeting the ceramide pathway goes upstream of glucose control to address the metabolic environment that causes insulin resistance.

SX-Fraction and the Insulin Receptor: The Glycoprotein Most Studied for Diabetes

The most thoroughly characterized maitake extract for diabetes mechanisms is the SX-fraction — a water-soluble glycoprotein (a protein with sugar chains attached) extracted from maitake, structurally distinct from the beta-glucan polysaccharide called D-fraction that most people associate with maitake immune effects.

Konno's 2020 review in World Journal of Diabetes synthesized the entire SX-fraction research arc.^[2] The animal work, conducted primarily at Georgetown University's Department of Physiology by Dr. Harry Preuss and colleagues through the early 2000s, showed consistent blood glucose-lowering and insulin-sensitizing effects across multiple diabetic animal models. Critically, maitake extract lowered both blood glucose and circulating insulin simultaneously in those studies — which rules out the mechanism being "stimulate more insulin secretion" and confirms it is "make cells respond better to the insulin already present."

The in vitro work from Konno's 2013 study pinpointed the molecular target: the insulin receptor and IRS-1.^[3] SX-fraction activates both. Activate those two proteins in skeletal muscle cells, and glucose uptake follows. The 7-patient clinical data showed the same directional effect in humans.

For the deep dive on SX-fraction specifically, see Maitake SX-Fraction and Insulin Sensitivity. The Georgetown research arc is detailed in Maitake and Glucose Tolerance: The Georgetown University Clinical Research. For broader pharmacological context on how all of maitake's active fractions work, see The Pharmacology of Grifola frondosa: How Maitake Works.

Three Decades of Animal Studies: What Consistent Preclinical Evidence Looks Like

The mechanistic richness described above built up over time. The earliest characterization of anti-diabetic activity in maitake came from Kubo and colleagues in 1994, who identified a polysaccharide fraction in the maitake fruit body responsible for glucose-lowering effects in animal models. Horio and Ohtsuru followed in 2001, showing that maitake extract improved oral glucose tolerance in streptozotocin-induced diabetic rats — the same animal model used in Xiao's GLUT4 study 14 years later. The reproducibility across independent groups and decades gives the preclinical evidence its weight.

By 2009, the Natural Standard Research Collaboration had reviewed the accumulated evidence and characterized it as "promising" — a careful word choice acknowledging real effects without overstating their clinical translation.^[4]

The consistency across three decades, multiple research groups, multiple animal models, and multiple maitake fractions (polysaccharides F2/F3, alpha-glucan, SX-fraction glycoprotein, whole extract) is the real strength of the preclinical case. A single positive animal study is easy to dismiss. Dozens of them, from independent labs, showing the same direction of effect through different mechanisms, is a qualitatively different kind of evidence.

The counterargument — and it is legitimate — is that animal-to-human translation for metabolic interventions is notoriously unreliable. Many compounds that consistently lower blood glucose in rodent models fail to reproduce the effect in humans. The animal evidence establishes a plausible mechanism and justifies a human trial. It does not establish human efficacy.

For a detailed survey of glycemic control data across the animal evidence base, see Maitake and Blood Sugar: Research on Glycemic Control. For the molecular mechanisms underlying the GLUT4 and gut-glucose findings, see How Maitake Affects Glucose Metabolism.

Why No Randomized Trial Has Been Run (And What It Means for Interpreting the Evidence)

The Lindequist and Haertel 2020 review documented the absence of clinical trials across all medicinal mushrooms — an observation that raises an obvious question.^[1] The answer is structural, not scientific: medicinal mushroom research is funded largely by academic labs without pharmaceutical backing. Randomized controlled trials for metabolic conditions are expensive. The compounds aren't patentable. The conditions for a well-powered human trial haven't been assembled — not because the preclinical evidence is insufficient to justify one, but because the economic incentives for funding one don't exist.

The absence of an RCT is not evidence against maitake's effectiveness. It is evidence of a funding gap. That distinction matters.

The gap in human evidence also means real unknowns deserve plain acknowledgment. Maitake's glucose-lowering mechanisms overlap with how oral diabetes drugs work — particularly the insulin-sensitizing pathway. Taking maitake alongside diabetes medication could produce additive blood glucose lowering, which can cause hypoglycemia (blood glucose going too low). This isn't a general warning: it's a specific mechanistic concern grounded in how both interventions affect the same pathway. The animal studies that showed SX-fraction outperforming drug comparisons on insulin sensitivity metrics are the same studies making this interaction concern mechanistically plausible.

The dual metabolic effects documented in the Preuss group's animal studies — blood pressure and blood glucose improving simultaneously — also connect maitake's diabetes research to its cardiovascular research. Type 2 diabetes substantially increases heart disease risk, and the SX-fraction research suggests one intervention may address both risk factors through the same insulin-sensitizing mechanism. For the cardiovascular angle, see Maitake and Cardiovascular Risk Reduction.

The Bottom Line

Maitake shows consistent blood glucose-lowering effects in animal models through four distinct pathways: GLUT4 upregulation, SX-fraction-mediated insulin receptor activation, gut microbiota rebalancing, and ceramide/lipid pathway modulation. Published human data covers only 9 patients across two uncontrolled publications. The 7-patient pilot found 30-63% fasting glucose reductions in patients already on diabetes medication — a directionally consistent signal, but not confirmable as causal without a control group. The preclinical evidence is mechanistically rich enough to justify a rigorous human trial; that trial has not yet been conducted.

Frequently Asked Questions

Is there clinical evidence for maitake treating type 2 diabetes?

The published human evidence covers 9 patients total: a 7-patient pilot study from 2013 showing 30-63% fasting glucose reductions in patients on diabetes medication, and a 2001 letter to the editor reporting possible glucose reduction in 2 patients. Neither was a randomized controlled trial. The animal evidence is extensive and consistent, but rigorous human trials do not yet exist.

Can maitake mushroom help with type 2 diabetes?

Animal research consistently shows maitake lowers blood glucose through multiple mechanisms, including GLUT4 upregulation, insulin receptor sensitization via SX-fraction, and gut microbiota rebalancing. A small 7-patient pilot study found large fasting glucose reductions. The human evidence is too limited to conclude maitake is an effective treatment for type 2 diabetes, but the direction of preclinical evidence and early human data warrants further investigation.

Does maitake replace diabetes medication?

No evidence supports using maitake to replace prescribed diabetes medication. The human data is from 9 patients without control groups. Maitake's glucose-lowering mechanisms overlap with how oral diabetes drugs work — taking both could potentially produce additive blood glucose lowering, which can cause hypoglycemia. The animal studies showing maitake's effects all used it alongside, not instead of, pharmacological comparisons.

What mushroom is best for type 2 diabetes?

Maitake has more published preclinical evidence specifically for type 2 diabetes mechanisms than most medicinal mushrooms, including a characterized glycoprotein fraction (SX-fraction) with a known insulin receptor mechanism and four identified glucose-lowering pathways. A 2020 clinical trial review found rigorous human RCT evidence is absent for all medicinal mushrooms in type 2 diabetes, so no mushroom currently has a clinical trial basis for being recommended as a diabetes treatment.

How long does maitake take to work for blood sugar?

The 7-patient pilot used SX-fraction supplementation over two to four weeks and observed fasting glucose reductions within that timeframe. Animal studies typically show effects within two to four weeks of daily administration at the doses tested. These timeframes come from uncontrolled or preclinical settings; how long effects would take in a properly controlled human trial is unknown.

What is the strongest evidence for maitake and diabetes?

The strongest single piece of evidence is the 2013 pilot study by Konno, which confirmed the mechanism at the cellular level — SX-fraction activating the insulin receptor and IRS-1 in skeletal muscle cells — and reported 30-63% fasting glucose reductions in 7 patients. The cellular mechanism confirmation is meaningful. The clinical data is too small to draw strong conclusions from independently, but it points in the same direction as three decades of animal research across multiple models and fractions.

Sources & References

1. 1RTHM-00632·Lindequist, Ulrike et al. (2020). “Medicinal Mushrooms for Treatment of Type 2 Diabetes: An Update on Clinical Trials..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-01222·Konno, Sensuke (2020). “SX-fraction: Promise for novel treatment of type 2 diabetes..” World journal of diabetes.Study breakdown →PubMed →↩
3. 3RTHM-00533·Konno, Sensuke et al. (2013). “Possible hypoglycemic action of SX-fraction targeting insulin signal transduction pathway..” International journal of general medicine.Study breakdown →PubMed →↩
4. 4RTHM-00319·Ulbricht, Catherine et al. (2009). “Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration..” Journal of the Society for Integrative Oncology.Study breakdown →PubMed →↩
5. 5RTHM-00410·Xiao, Chun et al. (2015). “Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats..” Food & function.Study breakdown →PubMed →↩
6. 6RTHM-00113·Hong, Lei et al. (2007). “Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice..” The Journal of pharmacy and pharmacology.Study breakdown →PubMed →↩
7. 7RTHM-01042·Chen, Yuqing et al. (2019). “Hypoglycemic activity and gut microbiota regulation of a novel polysaccharide from Grifola frondosa in type 2 diabetic mice..” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.Study breakdown →PubMed →↩
8. 8RTHM-01193·Guo, Wei-Ling et al. (2020). “Hypoglycemic and hypolipidemic activities of Grifola frondosa polysaccharides and their relationships with the modulation of intestinal microflora in diabetic mice induced by high-fat diet and streptozotocin..” International journal of biological macromolecules.Study breakdown →PubMed →↩
9. 9RTHM-01272·Pan, Yuyang et al. (2020). “Regulatory effect of Grifola frondosa extract rich in polysaccharides and organic acids on glycolipid metabolism and gut microbiota in rats..” International journal of biological macromolecules.Study breakdown →PubMed →↩
10. 10RTHM-01369·Jiang, Xue et al. (2021). “Anti-obesity effects of Grifola frondosa through the modulation of lipid metabolism via ceramide in mice fed a high-fat diet..” Food & function.Study breakdown →PubMed →↩